Open this publication in new window or tab >>KTH, School of Engineering Sciences in Chemistry, Biotechnology and Health (CBH), Protein Science, Affinity Proteomics. KTH, Centres, Science for Life Laboratory, SciLifeLab.
MSF Epictr Mbarara Res Ctr, Mbarara, Uganda..
Uppsala Univ, Dept Womens & Childrens Hlth, Int Maternal & Child Hlth, Uppsala, Sweden..
Mbarara Univ Sci & Technol, Fac Med, Dept Paediat & Child Hlth, Mbarara, Uganda..
Karolinska Univ Hosp, Dept Microbiol Tumor & Cell Biol, BioClinicum, Stockholm, Sweden..
Mbarara Univ Sci & Technol, Fac Med, Dept Paediat & Child Hlth, Mbarara, Uganda.;Holy Innocents Childrens Hosp, Mbarara, Uganda..
KTH, Centres, Science for Life Laboratory, SciLifeLab. KTH, School of Engineering Sciences in Chemistry, Biotechnology and Health (CBH), Protein Science, Affinity Proteomics.
Mbarara Univ Sci & Technol, Fac Med, Dept Paediat & Child Hlth, Mbarara, Uganda.;Holy Innocents Childrens Hosp, Mbarara, Uganda..
Karolinska Univ Hosp, Dept Microbiol Tumor & Cell Biol, BioClinicum, Stockholm, Sweden.;Nanyang Technol Univ, SCELSE, Singapore, Singapore..
Mbarara Univ Sci & Technol, Fac Med, Dept Paediat & Child Hlth, Mbarara, Uganda.;MSF Epictr Mbarara Res Ctr, Mbarara, Uganda..
KTH, Centres, Science for Life Laboratory, SciLifeLab. KTH, School of Engineering Sciences in Chemistry, Biotechnology and Health (CBH), Protein Science, Nano Biotechnology.
KTH, School of Engineering Sciences in Chemistry, Biotechnology and Health (CBH), Protein Science, Nano Biotechnology. KTH, Centres, Science for Life Laboratory, SciLifeLab.
Mbarara Univ Sci & Technol, Fac Med, Dept Paediat & Child Hlth, Mbarara, Uganda.;MSF Epictr Mbarara Res Ctr, Mbarara, Uganda..
Karolinska Inst, Dept Global Publ Hlth, Tomtebodavagen 18 A, S-17177 Stockholm, Sweden..
Show others...
2020 (English)In: Journal of Medical Internet Research, E-ISSN 1438-8871, Vol. 22, no 11, article id e21430Article in journal (Refereed) Published
Abstract [en]
Background: A timely differential diagnostic is essential to identify the etiology of central nervous system (CNS) infections in children, in order to facilitate targeted treatment, manage patients, and improve clinical outcome. Objective: The Pediatric Infection-Point-of-Care (PI-POC) trial is investigating novel methods to improve and strengthen the differential diagnostics of suspected childhood CNS infections in low-income health systems such as those in Southwestern Uganda. This will be achieved by evaluating (1) a novel DNA-based diagnostic assay for CNS infections, (2) a commercially available multiplex PCR-based meningitis/encephalitis (ME) panel for clinical use in a facility-limited laboratory setting, (3) proteomics profiling of blood from children with severe CNS infection as compared to outpatient controls with fever yet not severely ill, and (4) Myxovirus resistance protein A (MxA) as a biomarker in blood for viral CNS infection. Further changes in the etiology of childhood CNS infections after the introduction of the pneumococcal conjugate vaccine against Streptococcus pneumoniae will be investigated. In addition, the carriage and invasive rate of Neisseria meningitidis will be recorded and serotyped, and the expression of its major virulence factor (polysaccharide capsule) will be investigated. Methods: The PI-POC trial is a prospective observational study of children including newborns up to 12 years of age with clinical features of CNS infection, and age-/sex-matched outpatient controls with fever yet not severely ill. Participants are recruited at 2 Pediatric clinics in Mbarara, Uganda. Cerebrospinal fluid (for cases only), blood, and nasopharyngeal (NP) swabs (for both cases and controls) sampled at both clinics are analyzed at the Epicentre Research Laboratory through gold-standard methods for CNS infection diagnosis (microscopy, biochemistry, and culture) and a commercially available ME panel for multiplex PCR analyses of the cerebrospinal fluid. An additional blood sample from cases is collected on day 3 after admission. After initial clinical analyses in Mbarara, samples will be transported to Stockholm, Sweden for (1) validation analyses of a novel nucleic acid-based POC test, (2) biomarker research, and (3) serotyping and molecular characterization of S. pneumoniae and N. meningitidis. Results: A pilot study was performed from January to April 2019. The PI-POC trial enrollment of patients begun in April 2019 and will continue until September 2020, to include up to 300 cases and controls. Preliminary results from the PI-POC study are expected by the end of 2020. Conclusions: The findings from the PI-POC study can potentially facilitate rapid etiological diagnosis of CNS infections in low-resource settings and allow for novel methods for determination of the severity of CNS infection in such environment.
Place, publisher, year, edition, pages
JMIR Publications Inc., 2020
Keywords
global health, central nervous system infections, pediatrics, diagnostics, low-resource settings, meningitis, Uganda, children
National Category
Clinical Medicine
Identifiers
urn:nbn:se:kth:diva-287422 (URN)10.2196/21430 (DOI)000585386100006 ()33146628 (PubMedID)2-s2.0-85096769705 (Scopus ID)
Note
QC 20201214
2020-12-142020-12-142024-01-17Bibliographically approved